DUBLIN–(BUSINESS WIRE)–The “Biologics Contract Development Market Size, Share & Trends Analysis Report by Source (Mammalian, Microbial), by Product Service Type, by Disease Indication (Oncology, Immunological Disorders), by Region, and Segment Forecasts, 2020 – 2027” report has been added to ResearchAndMarkets.com’s offering.
The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, expanding at a CAGR of 8.8% over the forecast period.
The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production.
Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.
Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors.
Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.
Biologics Contract Development Market Report Highlights
- Mammalian source emerged as the largest product segment in 2019, as the majority of research activities are being carried out using mammalian cell lines.
- The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs).
- North America dominated the market in 2019. An increase in strategic acquisitions and partnerships and a rise in demand for specialized testing services are likely to have a positive impact on the market.
- In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing adoption of advanced technologies
3.2.3 Increasing mergers and collaborations
3.2.4 Favourable environment for clinical trials in developing countries
3.2.5 Increasing outsourcing of R&D activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual property rights issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis-Porter’s
3.4.2 PESTEL Analysis
Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis
4.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
Chapter 5 Biologics Contract Development Market: Product Service Segment Analysis
5.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2016-2027 (USD Million)
220.127.116.11 Microbial Cell Line Development
18.104.22.168 Mammalian Cell Line Development
22.214.171.124.1 Others Market, 2016-2027 (USD Million)
5.3 Process Development
5.3.1 Process Development Market, 2016-2027 (USD Million)
5.3.2 Upstream Process Development
126.96.36.199 Upstream Process Development Market, 2016-2027 (USD Million)
188.8.131.52.2 Microbial Market, 2016-2027 (USD Million)
184.108.40.206.4 Mammalian Market, 2016-2027 (USD Million)
5.3.3 Downstream Process Development
220.127.116.11 Downstream Process Development, 2016-2027 (USD Million)
18.104.22.168.1 Impurity, Isolation, & Identification
22.214.171.124.3 Physicochemical Characterization
126.96.36.199.4 Physicochemical Characterization Market, 2016-2027 (USD Million)
188.8.131.52.5 Pharmaceutical Analysis
184.108.40.206.6 Pharmaceutical Analysis Market, 2016-2027 (USD Million)
5.4 Downstream Process, By Product
5.4.1 Mabs (Monoclonal Antibodies)
5.4.2 Recombinant Proteins
220.127.116.11 Recombinant Proteins Analysis Market, 2016-2027 (USD Million)
5.5 Other Product Service (Quality and Regulatory Services, Etc)
Chapter 6 Biologics Contract Development Market: Disease Indication Segment Analysis
6.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
6.3 Immunological Disorders
6.4 Cardiovascular Disorders
6.5 Haematological Disorders
Chapter 7 Biologics Contract Development Market: Regional Analysis
Chapter 8 Company Profiles
- Wuxi Biologics
- Abzena Ltd.
- FUJIFILM Diosynth Biotechnologies
- KBI Biopharma
- AGC Biologics
- SE Thermo Fischer (Patheon)
- Lakepharma, Inc.
- BioNova Scientific
- BI BioXcellence
- STC Biologics
For more information about this report visit https://www.researchandmarkets.com/r/udea8s
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900